Harm HogenEsch
Overview
Explore the profile of Harm HogenEsch including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
98
Citations
2252
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hernandez-Franco J, Jan I, Elzey B, HogenEsch H
NPJ Vaccines
. 2024 Aug;
9(1):149.
PMID: 39152131
A critical aspect of cancer vaccine development is the formulation with effective adjuvants. This study evaluated whether combining a cationic plant-derived nanoparticle adjuvant (Nano-11) with the clinically tested STING agonist...
2.
Bugybayeva D, Dumkliang E, Patil V, Yadagiri G, Suresh R, Singh M, et al.
Vaccines (Basel)
. 2024 Jun;
12(6).
PMID: 38932376
This study focuses on the development and characterization of an intranasal vaccine platform using adjuvanted nanoparticulate delivery of swine influenza A virus (SwIAV). The vaccine employed whole inactivated H1N2 SwIAV...
3.
Blake J, Thompson J, HogenEsch H, Ekenstedt K
Vaccine
. 2024 Apr;
42(12):3099-3106.
PMID: 38604911
Both genetic and non-genetic factors contribute to individual variation in the immune response to vaccination. Understanding how genetic background influences variation in both magnitude and persistence of vaccine-induced immunity is...
4.
Patil V, Hernandez-Franco J, Yadagiri G, Bugybayeva D, Dolatyabi S, Feliciano-Ruiz N, et al.
Vaccines (Basel)
. 2023 Nov;
11(11).
PMID: 38006039
Swine influenza A viruses (SwIAVs) are pathogens of both veterinary and medical significance. Intranasal (IN) vaccination has the potential to reduce flu infection. We investigated the efficacy of split SwIAV...
5.
Hernandez-Franco J, Yadagiri G, Patil V, Bugybayeva D, Dolatyabi S, Dumkliang E, et al.
Vaccines (Basel)
. 2023 Nov;
11(11).
PMID: 38006031
The development of cross-protective vaccines against the zoonotic swine influenza A virus (swIAV), a potential pandemic-causing agent, continues to be an urgent global health concern. Commercially available vaccines provide suboptimal...
6.
Laera D, HogenEsch H, OHagan D
Pharmaceutics
. 2023 Jul;
15(7).
PMID: 37514070
Aluminum-based adjuvants will continue to be a key component of currently approved and next generation vaccines, including important combination vaccines. The widespread use of aluminum adjuvants is due to their...
7.
Das D, HogenEsch H, Thangamani S
Front Immunol
. 2023 Apr;
14:1123200.
PMID: 37114044
, an emerging multi-drug resistant fungal pathogen, causes invasive infections in humans. The factors regulating the colonization of in host niches are not well understood. In this study, we examined...
8.
Doerr K, Salisbury S, HogenEsch H, San Miguel S, Reed W
J Am Vet Med Assoc
. 2023 Feb;
261(3):415.
PMID: 36812086
No abstract available.
9.
Doerr K, Salisbury S, HogenEsch H, San Miguel S, Reed W
Am J Vet Res
. 2023 Feb;
84(3).
PMID: 36749653
No abstract available.
10.
Franco J, Aryal U, HogenEsch H, Moore G
Am J Vet Res
. 2023 Jan;
84(3).
PMID: 36662608
Objective: To use proteomic analysis to identify qualitatively and quantitatively mammalian protein components of commercial veterinary vaccines against canine distemper, leptospirosis, borreliosis, and rabies. Sample: 25 licensed veterinary vaccines (from...